Showing results (351-360 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|September 22, 2011
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisAlice T Shaw, Beow Y Yeap, Benjamin J Solomon, et al.
The Lancet. Oncology|September 22, 2011
Prevention of CNS relapse in diffuse large B-cell lymphomaRobert Kridel, Pierre-Yves Dietrich
The Lancet. Oncology|February 4, 2012
Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCAugusto Caraceni, Geoffrey Hanks, Stein Kaasa, et al.
The Lancet. Oncology|January 20, 2012
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trialMichael Untch, Sibylle Loibl, Joachim Bischoff, et al.
The Lancet. Oncology|March 29, 2012
Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trialNicholas D James, Matthew R Sydes, Malcolm D Mason, et al.
The Lancet. Oncology|March 29, 2012
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trialJames Chih-Hsin Yang, Jin-Yuan Shih, Wu-Chou Su, et al.
The Lancet. Oncology|April 4, 2012
Tattoos, inks, and cancerNicolas Kluger, Virve Koljonen
The Lancet. Oncology|April 4, 2012
Genetic heterogeneity and cancer drug resistanceNicholas C Turner, Jorge S Reis-Filho
The Lancet. Oncology|April 17, 2012
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trialRalf-Dieter Hofheinz, Frederik Wenz, Stefan Post, et al.
The Lancet. Oncology|April 20, 2012
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development studyHashim U Ahmed, Richard G Hindley, Louise Dickinson, et al.
Pageof 336